{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T16:55:39Z","timestamp":1783875339047,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303643"],"award-info":[{"award-number":["82303643"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["SL2023A04J02374"],"award-info":[{"award-number":["SL2023A04J02374"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cllc.2024.12.002","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T21:39:39Z","timestamp":1733348379000},"page":"263-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease"],"prefix":"10.1016","volume":"26","author":[{"given":"Chang","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Si","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Neng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2024.12.002_bib0001","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41568-024-00700-y","article-title":"The path to leptomeningeal metastasis","volume":"24","author":"Remsik","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2024.12.002_bib0002","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.12.002_bib0003","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.12.002_bib0004","doi-asserted-by":"crossref","first-page":"15761","DOI":"10.1038\/ncomms15761","article-title":"Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1\/ALK inhibitor lorlatinib","volume":"8","author":"Collier","year":"2017","journal-title":"Nat Comm"},{"key":"10.1016\/j.cllc.2024.12.002_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1536012117736669","article-title":"Brain penetration of the ROS1\/ALK inhibitor Lorlatinib confirmed by PET","volume":"16","author":"Collier","year":"2017","journal-title":"Mol Imaging"},{"key":"10.1016\/j.cllc.2024.12.002_bib0006","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.12.002_bib0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain penetration of Lorlatinib: cumulative incidences of CNS and non-CNS progression with Lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.cllc.2024.12.002_bib0008","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of Lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non\u2013Small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.12.002_bib0009","article-title":"Phase II study of Lorlatinib in patients with anaplastic lymphoma kinase\u2013Positive lung cancer and CNS-specific relapse","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precision Oncol"},{"key":"10.1016\/j.cllc.2024.12.002_bib0010","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41571-023-00808-4","article-title":"Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer","volume":"20","author":"Pan","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cllc.2024.12.002_bib0011","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.12.002_bib0012","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"Le Rhun","year":"2019","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.cllc.2024.12.002_bib0013","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.cllc.2024.12.002_bib0014","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg Osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation\u2013Positive non\u2013Small cell lung cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424002651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424002651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:47:29Z","timestamp":1762548449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424002651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525730424002651"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.12.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}